News & Events about Acelrx Pharmaceuticals Inc.
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX Get Rating) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 878,500 shares, an increase of 12.5% from the November 30th total of 780,600 shares. Currently, 12.0% of ...
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX Get Rating) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 878,500 shares, an increase of 12.5% from the November 30th total of 780,600 shares. Approximately 12.0% of the...
AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock PR Newswire HAYWARD, Calif., Dec. 27, 2022 HAYWARD, Calif., Dec. 27, 2022...
AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022 AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic...
AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY Annual Meeting 2022 AcelRx Pharmaceuticals Announces Presentation of...